Evotec Tech Sells HTS/HCS System to Cincinnati’s GRI; Daiichi Selects Evotec for Compound Profiling
Evotec said this week that its Evotec Technologies division has installed a plate::explorer system with an Opera high-content screening extension to the Genome Research Institute at the University of Cincinnati and the Cincinnati Children’s Hospital Medical Center.
The new system will enable GRI and affiliate researchers to conduct high-throughput and high-content screening
In a separate announcement this week, Evotec said that it has been selected by Daiichi Pharmaceutical for medicinal chemistry and compound profiling.
Evotec scientists will work on two programs for Daiichi to identify lead structures for further progression into clinical trials. Evotec will provide compound design, parallel synthesis, computational chemistry, ADMET services, assay development, and compound profiling.
FTC Approves Thermo-Fisher Merger; Fisher to Divest Genevac Business
Thermo Electron said this week that the US Federal Trade Commission has approved its $10.6-billion merger with Fisher Scientific International.
Thermo said the FTC has approved a consent order requiring Fisher to divest its $17-million Genevac business and that it has granted the companies "early termination" of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.
Fisher announced its plan to divest a $17-million product line in August, but did not disclose which of its subsidiaries would be affected.
Thermo said that no further regulatory review is required in the US to close the merger.
In Europe, the deadline for the European Commission to rule on the merger has been extended to Nov. 9. Thermo said that the planned divestiture of the Genevac business should “resolve any issues raised by the European Commission regarding the merger.”
The companies plan to close the merger on Nov. 9, assuming the EC clears the transaction.
Genevac is a vacuum pump manufacturer founded in 1990. Apogent Technologies acquired it in 2000, and Apogent then merged with Fisher Scientific in 2004.
According to its website, Genevac employs around 85 people, and most are based at the company’s manufacturing, R&D, and marketing headquarters in Ipswich, UK.
Genevac also has a US subsidiary based in Valley Cottage, NY.
GE Healthcare's Q3 Revenues Rise 9 Percent as Earnings Jump 19 Percent
GE Healthcare this week said that third-quarter revenues climbed 9 percent as earnings increased 19 percent.
For the quarter ended Sept. 30, GE Healthcare generated $3.9 billion in revenues, up from $3.6 billion during the same quarter in 2005.
GE Healthcare's earnings for the quarter increased to $700 million from $589 million in the third quarter of 2005.
GE's total revenues for the quarter were $40.9 billion, up from $36.4 billion during the same period last year.
GE did not break out its research and development expenses for the Healthcare segment.
As of Sept. 30, GE reported $59.4 billion in cash and marketable securities.